{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:54:06Z","timestamp":1792155246742,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this retrospective multicentric study was to compare the tumour response rates of Balloon-occluded Transarterial Chemoembolisation (B-TACE) to non-B-TACE using propensity score matching (PSM) in patients with hepatocellular carcinoma and to investigate the clinical benefit, such as lower rates of TACE re-intervention achieved using B-TACE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and Methods<\/jats:title>\n                <jats:p>The B-TACE procedures (<jats:italic>n<\/jats:italic>\u2009=\u200996 patients) were compared with a control group of non-B-TACE treatments (<jats:italic>n<\/jats:italic>\u2009=\u2009434 pts), performed with conventional (cTACE) or drug-eluting microspheres TACE (DEM-TACE). Data were collected from six European centres from 2015 to 2019.<\/jats:p>\n                <jats:p>Objective responses (OR) and complete response (CR) rates after the first session and the number of TACE re-interventions were evaluated using PSM (91 patients per arm).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The best target OR after PSM were similar for both B-TACE and non-B-TACE (90.1% and 86.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.644); however, CR at 1\u20136\u00a0months was significantly higher for B-TACE (59.3% vs. 41.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.026). Patients treated with B-TACE had a significantly lower retreatment rate during the first 6\u00a0months (9.9%% vs. 22.0%, <jats:italic>p<\/jats:italic>\u2009=\u20090.041). Post-embolisation syndrome (PES) rates were 8.8% in non-B-TACE and 41.8% in B-TACE (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), with no significant differences between groups regarding major adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>B-TACE is safe and effective, achieving higher CR rates than non-B-TACE. Patients undergoing B-TACE had a significantly lower retreatment rate within the first 6\u00a0months but higher PES rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Level of Evidence III<\/jats:title>\n                <jats:p>Level 3, retrospective study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00270-021-02805-5","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T21:02:36Z","timestamp":1615496556000},"page":"1048-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Rita","family":"Golfieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gontran","family":"Verset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fucilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandro","family":"Paccapelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierleone","family":"Lucatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Magand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Rode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"De Baere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"issue":"1","key":"2805_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","volume":"33","author":"J Lammer","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol. 2010;33(1):41\u201352. https:\/\/doi.org\/10.1007\/s00270-009-9711-7.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"2","key":"2805_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/bjc.2014.199","volume":"111","author":"R Golfieri","year":"2014","unstructured":"Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255\u201364. https:\/\/doi.org\/10.1038\/bjc.2014.199.","journal-title":"Br J Cancer"},{"issue":"6","key":"2805_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","volume":"48","author":"A Facciorusso","year":"2016","unstructured":"Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48(6):571\u20137. https:\/\/doi.org\/10.1016\/j.dld.2016.02.005.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"2805_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol"},{"issue":"10127","key":"2805_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314. https:\/\/doi.org\/10.1016\/s0140-6736(18)30010-2.","journal-title":"Lancet"},{"issue":"2","key":"2805_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913.03.50047","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018;68(2):723\u201350. https:\/\/doi.org\/10.1002\/hep.29913.03.50047.","journal-title":"Hepatology"},{"issue":"4","key":"2805_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/cncr.11106","volume":"97","author":"S Iwamoto","year":"2003","unstructured":"Iwamoto S, Sanefuji H, Okuda K. Angiographic subsegmentectomy for the treatment of patients with small hepatocellular carcinoma. Cancer. 2003;97(4):1051\u20136. https:\/\/doi.org\/10.1002\/cncr.11106.","journal-title":"Cancer"},{"issue":"1","key":"2805_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1148\/radiology.188.1.8390073","volume":"188","author":"O Matsui","year":"1993","unstructured":"Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993;188(1):79\u201383. https:\/\/doi.org\/10.1148\/radiology.188.1.8390073.","journal-title":"Radiology"},{"issue":"4","key":"2805_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hep Intl. 2017;11(4):317\u201370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9.","journal-title":"Hep Intl"},{"issue":"3","key":"2805_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000507370","volume":"9","author":"M Kudo","year":"2020","unstructured":"Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: asia-pacific primary liver cancer expert consensus statements. Liver Cancer. 2020;9(3):245\u201360. https:\/\/doi.org\/10.1159\/000507370.","journal-title":"Liver Cancer"},{"issue":"6","key":"2805_CR11","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3348\/kjr.2008.9.6.534","volume":"9","author":"SK Ji","year":"2008","unstructured":"Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, et al. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol. 2008;9(6):534\u201340. https:\/\/doi.org\/10.3348\/kjr.2008.9.6.534.","journal-title":"Korean J Radiol"},{"issue":"Suppl","key":"2805_CR12","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1007\/bf00686674","volume":"33","author":"O Matsui","year":"1994","unstructured":"Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demachi H. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol. 1994;33(Suppl):S84\u20138. https:\/\/doi.org\/10.1007\/bf00686674.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2805_CR13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jvir.2006.12.004","volume":"18","author":"S Miyayama","year":"2007","unstructured":"Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 2007;18(3):365\u201376. https:\/\/doi.org\/10.1016\/j.jvir.2006.12.004.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"2805_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3348\/kjr.2007.8.2.111","volume":"8","author":"SH Park","year":"2007","unstructured":"Park SH, Cho YK, Ahn YS, Park YO, Kim JK, Chung JW. Local recurrence of hepatocellular carcinoma after segmental transarterial chemoembolization: risk estimates based on multiple prognostic factors. Korean J Radiol. 2007;8(2):111\u20139. https:\/\/doi.org\/10.3348\/kjr.2007.8.2.111.","journal-title":"Korean J Radiol"},{"issue":"5","key":"2805_CR15","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/hep.24246","volume":"53","author":"R Golfieri","year":"2011","unstructured":"Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology. 2011;53(5):1580\u20139. https:\/\/doi.org\/10.1002\/hep.24246.","journal-title":"Hepatology"},{"issue":"9","key":"2805_CR16","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jvir.2016.04.014","volume":"27","author":"S Miyayama","year":"2016","unstructured":"Miyayama S, Matsui O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome. J Vasc Interv Radiol. 2016;27(9):1269\u201378. https:\/\/doi.org\/10.1016\/j.jvir.2016.04.014.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"2805_CR17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/BF02577719","volume":"14","author":"H Demachi","year":"1991","unstructured":"Demachi H, Matsui O, Takashima T. Scanning electron microscopy of intrahepatic microvasculature casts following experimental hepatic artery embolization. Cardiovasc Interv Radiol. 1991;14(3):158. https:\/\/doi.org\/10.1007\/BF02577719.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"2","key":"2805_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hep.510310203","volume":"31","author":"W Ekataksin","year":"2000","unstructured":"Ekataksin W. The isolated artery: an intrahepatic arterial pathway that can bypass the lobular parenchyma in mammalian livers. Hepatology. 2000;31(2):269\u201379. https:\/\/doi.org\/10.1002\/hep.510310203.","journal-title":"Hepatology"},{"issue":"9399","key":"2805_CR19","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/s0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907\u201317. https:\/\/doi.org\/10.1016\/s0140-6736(03)14964-1.","journal-title":"Lancet"},{"issue":"6","key":"2805_CR20","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.jhep.2015.01.022","volume":"62","author":"BK Kim","year":"2015","unstructured":"Kim BK, Kim SU, Kim KA, Chung YE, Kim MJ, Park MS, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015;62(6):1304\u201310. https:\/\/doi.org\/10.1016\/j.jhep.2015.01.022.","journal-title":"J Hepatol"},{"issue":"4","key":"2805_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jvir.2012.12.013","volume":"24","author":"R Golfieri","year":"2013","unstructured":"Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013;24(4):509\u201317. https:\/\/doi.org\/10.1016\/j.jvir.2012.12.013.","journal-title":"J Vasc Interv Radiol"},{"key":"2805_CR22","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1200\/JCO.2018.36.15_suppl.4018","volume":"36","author":"M Peck-Radosavljevic","year":"2018","unstructured":"Peck-Radosavljevic M, Kudo M, Raoul J-L, Lee HC, Decaens T, Heo J, et al. Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis. J Clin Oncol. 2018;36:4018. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.4018.","journal-title":"J Clin Oncol"},{"key":"2805_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4254\/wjh.v10.i7.485","volume":"26","author":"T Irie","year":"2009","unstructured":"Irie T, Kuramochi M, Takahashi N. Improved accumulation of lipiodol under balloon-occluded transarterial chemoembolization (B-TACE) for hepatocellular carcinoma: measurement of blood pressure at the embolized artery before and after balloon inflation. Jpn J Interv Radiol. 2009;26:49\u201354. https:\/\/doi.org\/10.4254\/wjh.v10.i7.485.","journal-title":"Jpn J Interv Radiol"},{"issue":"3","key":"2805_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00270-012-0476-z","volume":"36","author":"T Irie","year":"2013","unstructured":"Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Interv Radiol. 2013;36(3):706\u201313. https:\/\/doi.org\/10.1007\/s00270-012-0476-z.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"2","key":"2805_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1148\/radiology.167.2.2833765","volume":"167","author":"H Nakamura","year":"1988","unstructured":"Nakamura H, Hashimoto T, Oi H, Sawada S. Iodized oil in the portal vein after arterial embolization. Radiology. 1988;167(2):415\u20137. https:\/\/doi.org\/10.1148\/radiology.167.2.2833765.","journal-title":"Radiology"},{"issue":"6","key":"2805_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/hepr.12403","volume":"45","author":"H Arai","year":"2015","unstructured":"Arai H, Abe T, Takayama H, Toyoda M, Ueno T, Kakizaki S, et al. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol Res. 2015;45(6):663\u20136. https:\/\/doi.org\/10.1111\/hepr.12403.","journal-title":"Hepatol Res"},{"issue":"2","key":"2805_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/hepr.12912","volume":"48","author":"T Hatanaka","year":"2018","unstructured":"Hatanaka T, Arai H, Shibasaki M, Tojima H, Takizawa D, Toyoda M, et al. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: a retrospective cohort study. Hepatol Res. 2018;48(2):165\u201375. https:\/\/doi.org\/10.1111\/hepr.12912.","journal-title":"Hepatol Res"},{"issue":"3","key":"2805_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00270-015-1237-6","volume":"39","author":"M Maruyama","year":"2016","unstructured":"Maruyama M, Yoshizako T, Nakamura T, Nakamura M, Yoshida R, Kitagaki H. Initial experience with balloon-occluded trans-catheter arterial chemoembolization (b-tace) for hepatocellular carcinoma. Cardiovasc Interv Radiol. 2016;39(3):359\u201366. https:\/\/doi.org\/10.1007\/s00270-015-1237-6.","journal-title":"Cardiovasc Interv Radiol"},{"key":"2805_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000440628","volume":"89","author":"Y Minami","year":"2015","unstructured":"Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, et al. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma: a single-center experience. Oncology. 2015;89:27\u201332. https:\/\/doi.org\/10.1159\/000440628.","journal-title":"Oncology"},{"issue":"1","key":"2805_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132.","journal-title":"Semin Liver Dis"},{"issue":"8","key":"2805_CR31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","volume":"40","author":"DK Filippiadis","year":"2017","unstructured":"Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira P. CIRSE quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Interv Radiol. 2017;40(8):1141\u20136. https:\/\/doi.org\/10.1007\/s00270-017-1703-4.","journal-title":"Cardiovasc Interv Radiol"},{"key":"2805_CR32","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 (2017). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic applications\/docs\/CTCAE v5 Quick Reference 8.5x11.pdf"},{"issue":"6","key":"2805_CR33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","volume":"55","author":"R Gillmore","year":"2011","unstructured":"Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309\u201316. https:\/\/doi.org\/10.1016\/j.jhep.2011.03.007.","journal-title":"J Hepatol"},{"issue":"2","key":"2805_CR34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1148\/radiol.11110282","volume":"262","author":"JH Shim","year":"2012","unstructured":"Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? a validation study of old and new models. Radiology. 2012;262(2):708\u201318. https:\/\/doi.org\/10.1148\/radiol.11110282.","journal-title":"Radiology"},{"issue":"7","key":"2805_CR35","doi-asserted-by":"publisher","first-page":"e0133488","DOI":"10.1371\/journal.pone.0133488","volume":"10","author":"B Vincenzi","year":"2015","unstructured":"Vincenzi B, Di Maio M, Silletta M, D\u2019Onofrio L, Spoto C, Piccirillo MC, et al. Prognostic relevance of objective response according to easl criteria and mrecist criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS ONE. 2015;10(7):e0133488. https:\/\/doi.org\/10.1371\/journal.pone.0133488.","journal-title":"PLoS ONE"},{"issue":"1","key":"2805_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106\u201316. https:\/\/doi.org\/10.1002\/hep.28453.","journal-title":"Hepatology"},{"issue":"1","key":"2805_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/hep.28554","volume":"64","author":"F Trevisani","year":"2016","unstructured":"Trevisani F, Golfieri R. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: where are we now? Hepatology (Baltimore, MD). 2016;64(1):23\u20135. https:\/\/doi.org\/10.1002\/hep.28554.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"11","key":"2805_CR38","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.3390\/cancers12113405","volume":"12","author":"T De Baere","year":"2020","unstructured":"De Baere T, Guiu B, Ronot M, Chevallier P, Sergent G, Tancredi I, et al. Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. Cancers (Basel). 2020;12(11):3405. https:\/\/doi.org\/10.3390\/cancers12113405.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2805_CR39","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.jvir.2017.07.020","volume":"28","author":"C Aliberti","year":"2017","unstructured":"Aliberti C, Carandina R, Lonardi S, Dadduzio V, Vitale A, Gringeri E, et al. Transarterial chemoembolization with small drug-eluting beads in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an italian center. J Vasc Interv Radiol. 2017;28(11):1495\u2013502. https:\/\/doi.org\/10.1016\/j.jvir.2017.07.020.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"2805_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jvir.2018.02.004","volume":"29","author":"F Veloso Gomes","year":"2018","unstructured":"Veloso Gomes F, Oliveira JA, Correia MT, Costa NV, Abrantes J, Torres D, et al. Chemoembolization of hepatocellular carcinoma with drug-eluting polyethylene glycol embolic agents: single-center retrospective analysis in 302 patients. J Vasc Interv Radiol. 2018;29(6):841\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2018.02.004.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"2805_CR41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2214\/AJR.15.14758","volume":"206","author":"LC Casadaban","year":"2016","unstructured":"Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE Jr, Gaba RC. Conventional ethiodized oil transarterial chemoembolization for treatment of hepatocellular carcinoma: contemporary single-center review of clinical outcomes. AJR Am J Roentgenol. 2016;206(3):645\u201354. https:\/\/doi.org\/10.2214\/AJR.15.14758.","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"2805_CR42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3748\/wjg.v26.i3.324","volume":"26","author":"GS Roth","year":"2020","unstructured":"Roth GS, Teyssier Y, Abousalihac M, Seigneurin A, Ghelfi J, Sengel C, et al. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. World J Gastroenterol. 2020;26(3):324\u201334. https:\/\/doi.org\/10.3748\/wjg.v26.i3.324.","journal-title":"World J Gastroenterol"},{"key":"2805_CR43","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00270-017-1839-2","volume":"41","author":"G Richter","year":"2018","unstructured":"Richter G, Radeleff B, Stroszczynski C, Pereira P, Helmberger T, Barakat M, et al. Safety and feasibility of chemoembolization with doxorubicin-loaded small calibrated microspheres in patients with hepatocellular carcinoma: results of the miracle i prospective multicenter study. Cardiovasc Interv Radiol. 2018;41:587\u201393. https:\/\/doi.org\/10.1007\/s00270-017-1839-2.","journal-title":"Cardiovasc Interv Radiol"},{"key":"2805_CR44","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1148\/radiol.2019182399","volume":"291","author":"B Guiu","year":"2019","unstructured":"Guiu B, Chevallier P, Assenat E, Barbier E, Merle P, Bouvier A, et al. Idarubicin-loaded Beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial. Radiology. 2019;291:801\u20138. https:\/\/doi.org\/10.1148\/radiol.2019182399.","journal-title":"Radiology"},{"issue":"7","key":"2805_CR45","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/cancers11070987","volume":"11","author":"B Guiu","year":"2019","unstructured":"Guiu B, Colombat S, Piron L, Hermida M, Allimant C, Pierredon-Foulogne MA, et al. Transarterial chemoembolization of hepatocellular carcinoma with idarubicin-loaded tandem drug-eluting embolics. Cancers. 2019;11(7):987. https:\/\/doi.org\/10.3390\/cancers11070987.","journal-title":"Cancers"},{"issue":"3","key":"2805_CR46","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jvir.2018.11.026","volume":"30","author":"DT Goldman","year":"2019","unstructured":"Goldman DT, Singh M, Patel RS, Nowakowski FS, Bishay V, Ranade M, et al. Balloon-occluded transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center us preliminary experience. J Vasc Interv Radiol. 2019;30(3):342\u20136. https:\/\/doi.org\/10.1016\/j.jvir.2018.11.026.","journal-title":"J Vasc Interv Radiol"},{"key":"2805_CR47","doi-asserted-by":"publisher","DOI":"10.2217\/hep-2020-0022","author":"AM Bucalau","year":"2020","unstructured":"Bucalau AM, Tancredi I, Pezzullo M, Leveque R, Picchia S, Van Laethem JL, Verset G. Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. Hepatic oncol Future Med. 2020. https:\/\/doi.org\/10.2217\/hep-2020-0022.","journal-title":"Hepatic oncol Future Med"},{"issue":"6","key":"2805_CR48","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00270-019-02192-y","volume":"42","author":"P Lucatelli","year":"2019","unstructured":"Lucatelli P, Ginnani Corradini L, De Rubeis G, Rocco B, Basilico F, Cannavale A, et al. Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-eluting embolics: safety and preliminary results. Cardiovasc Interv Radiol. 2019;42(6):853\u201362. https:\/\/doi.org\/10.1007\/s00270-019-02192-y.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"7","key":"2805_CR49","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4254\/wjh.v10.i7.485","volume":"10","author":"T Hatanaka","year":"2018","unstructured":"Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2018;10(7):485\u201395. https:\/\/doi.org\/10.4254\/wjh.v10.i7.485.","journal-title":"World J Hepatol"},{"issue":"4","key":"2805_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/hepr.12754","volume":"47","author":"Y Kawamura","year":"2017","unstructured":"Kawamura Y, Ikeda K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, et al. Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules. Hepatol Res. 2017;47(4):338\u201346. https:\/\/doi.org\/10.1111\/hepr.12754.","journal-title":"Hepatol Res"},{"key":"2805_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40064-016-1880-7","volume":"5","author":"Y Asayama","year":"2016","unstructured":"Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y, Okamoto D, et al. Hemodynamic changes under balloon occlusion of hepatic artery: predictor of the short-term therapeutic effect of balloon-occluded transcatheter arterial chemolipiodolization using miriplatin for hepatocellular carcinoma. Springerplus. 2016;5:157. https:\/\/doi.org\/10.1186\/s40064-016-1880-7.","journal-title":"Springerplus"},{"issue":"10","key":"2805_CR52","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1007\/s00330-020-06911-9","volume":"30","author":"PH Kim","year":"2020","unstructured":"Kim PH, Gwon DI, Kim JW, Chu HH, Kim JH. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. Eur Radiol. 2020;30(10):5650\u201362. https:\/\/doi.org\/10.1007\/s00330-020-06911-9.","journal-title":"Eur Radiol"},{"issue":"Suppl","key":"2805_CR53","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1007\/BF00647229","volume":"23","author":"M Kojiro","year":"1989","unstructured":"Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol. 1989;23(Suppl):S4-8. https:\/\/doi.org\/10.1007\/BF00647229.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"2805_CR54","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/lt.22314","volume":"17","author":"C Zen","year":"2011","unstructured":"Zen C, Zen Y, Mitry RR, Corbeil D, Karbanova J, O\u2019Grady J, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011;17(8):943\u201354. https:\/\/doi.org\/10.1002\/lt.22314.","journal-title":"Liver Transpl"},{"issue":"9","key":"2805_CR55","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1872-034X.2011.00836.x","volume":"41","author":"S Miyayama","year":"2011","unstructured":"Miyayama S, Matsui O, Zen Y, Yamashiro M, Hattori Y, Orito N, et al. Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: observation on CT during arterial portography. Hepatol Res. 2011;41(9):853\u201366. https:\/\/doi.org\/10.1111\/j.1872-034X.2011.00836.x.","journal-title":"Hepatol Res"},{"issue":"2","key":"2805_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000492822","volume":"96","author":"T Shirono","year":"2019","unstructured":"Shirono T, Iwamoto H, Niizeki T, Shimose S, Nakano M, Satani M, et al. Epirubicin is more effective than Miriplatin in balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Oncology. 2019;96(2):79\u201386. https:\/\/doi.org\/10.1159\/000492822.","journal-title":"Oncology"},{"issue":"2","key":"2805_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/hepr.12564","volume":"46","author":"T Irie","year":"2016","unstructured":"Irie T, Kuramochi M, Kamoshida T, Takahashi N. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: retrospective comparison with conventional super-selective TACE. Hepatol Res. 2016;46(2):209\u201314. https:\/\/doi.org\/10.1111\/hepr.12564.","journal-title":"Hepatol Res"},{"issue":"3","key":"2805_CR58","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1111\/hepr.12527","volume":"46","author":"M Ogawa","year":"2016","unstructured":"Ogawa M, Takayasu K, Hirayama M, Miura T, Shiozawa K, Abe M, et al. Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: short-term results. Hepatol Res. 2016;46(3):E60\u20139. https:\/\/doi.org\/10.1111\/hepr.12527.","journal-title":"Hepatol Res"},{"issue":"7","key":"2805_CR59","doi-asserted-by":"publisher","first-page":"e103009","DOI":"10.1371\/journal.pone.0103009","volume":"9","author":"T Ishikawa","year":"2014","unstructured":"Ishikawa T, Abe S, Inoue R, Sugano T, Watanabe Y, Iwanaga A, et al. Predictive factor of local recurrence after balloon-occluded TACE with miriplatin (MPT) in hepatocellular carcinoma. PLoS ONE. 2014;9(7):e103009. https:\/\/doi.org\/10.1371\/journal.pone.0103009.","journal-title":"PLoS ONE"},{"issue":"1","key":"2805_CR60","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/1471-2407-14-601","volume":"14","author":"E Terzi","year":"2013","unstructured":"Terzi E, Piscaglia F, Forlani L, Mosconi C, Renzulli M, Bolondi L, et al. TACE performed in patients with a single nodule of Hepatocellular Carcinoma. BMC Cancer. 2013;14(1):601. https:\/\/doi.org\/10.1186\/1471-2407-14-601.","journal-title":"BMC Cancer"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-021-02805-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-021-02805-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-021-02805-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T21:13:46Z","timestamp":1623273226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-021-02805-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["2805"],"URL":"https:\/\/doi.org\/10.1007\/s00270-021-02805-5","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The Authors declares that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}